RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 23.07.2020 | 13:36

RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

RHÖN-KLINIKUM Aktiengesellschaft
23.07.2020 / 13:36
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer
Name: RHÖN-KLINIKUM Aktiengesellschaft
Street: Salzburger Leite 1
Postal code: 97616
City: Bad Neustadt a.d.Saale
Germany
Legal Entity Identifier (LEI): 529900MVGMIVUDQY9E20

2. Reason for notification
X Acquisition/disposal of shares with voting rights
X Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Natural person (first name, surname): Dr. Bernard große Broermann
Date of birth: 20 Nov 1943

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
AMR Holding GmbH

5. Date on which threshold was crossed or reached:
22 Jul 2020

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 93.38 % 0.00 % 93.38 % 66962470
Previous notification 92.58 % 43.59 % 92.58 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0007042301 360 62526065 0.0005 % 93.37 %
Total 62526425 93.38 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
0 0.00 %
    Total 0 0.00 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
0 0.00 %
      Total 0 0.00 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Dr. Bernard große Broermann % % %
Asklepios Kliniken Management GmbH % % %
Asklepios Kliniken GmbH & Co. KGaA % % %
AMR Holding GmbH 92.27 % % 92.27 %
- % % %
Dr. Bernard große Broermann % % %
Broermann Holding GmbH % % %
Asklepios Kliniken GmbH & Co. KGaA % % %
AMR Holding GmbH 92.27 % % 92.27 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
The Asklepios Kliniken GmbH & Co. KGaA contributed an interest of 43.59% of the share capital and voting rights in RHÖN-KLINIKUM Aktiengesellschaft to AMR Holding GmbH in accordance with the joint venture agreement dated 28 February 2020. 

Date
23 Jul 2020



23.07.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Bayer Aktiengesellschaft: Bayer beschleunigt Transformation, um dem herausfordernden Marktumfeld gerecht zu werden und zusätzliche Wachstumsinvestitionen zu ermöglichen

30. September 2020, 19:10

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

30. September 2020